Working… Menu

Neoadjuvant Therapy for Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01146795
Recruitment Status : Completed
First Posted : June 22, 2010
Results First Posted : February 9, 2021
Last Update Posted : February 9, 2021
Genentech, Inc.
Information provided by (Responsible Party):
Jason D. Wright, Columbia University

Brief Summary:
This study is to determine the feasibility of administering neoadjuvant carboplatin, paclitaxel, and bevacizumab without excessive dose modification or cycle delay in patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. This study will also investigate the rate of optimal cytoreduction, response rate and progression free and overall survival, and to assess the quality of life for patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer treated with neoadjuvant carboplatin, paclitaxel and bevacizumab.

Condition or disease Intervention/treatment Phase
Epithelial Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Cancer Drug: Carboplatin Drug: Paclitaxel Drug: Bevacizumab Phase 2

Detailed Description:

Initial treatment for ovarian cancer is usually surgical cytoreduction followed by adjuvant platinum and taxane chemotherapy. At the time of diagnosis over 75% of patients present with stage III or IV disease that has spread into the peritoneal cavity or distally. Despite a number of new chemotherapeutic regimens survival has improved only modestly over the preceding two decades. While overall 5-year survival has improved from 30% to 50%, 5-year survival remains only 25% for women with advanced stage disease. Given these findings it is clear that improved strategies for the delivery of cytotoxic and biologic agents are needed for women with advanced stage epithelial ovarian cancer.

A newer drug, called bevacizumab, has been approved by the U.S. Food and Drug Administration (FDA) for use in combination with chemotherapy in patients with colon cancer, lung cancer, and some types of breast cancer that have spread to distant sites in the body. A critical question which will need to be answered is whether or not it is feasible to administer a combination of bevacizumab with standard cytotoxic therapy using a neo-adjuvant approach for patients with epithelial cancer of the ovary, fallopian tube, or primary peritoneum.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Actual Study Start Date : May 17, 2010
Actual Primary Completion Date : April 13, 2015
Actual Study Completion Date : April 13, 2015

Arm Intervention/treatment
Experimental: Carboplatin, Paclitaxel, and Bevacizumab

Three 21 day cycles of carboplatin, paclitaxel, and bevacizumab.

After 3 cycles of chemotherapy patients will be considered for surgical cytoreduction. Patients must fulfill all criteria to be considered eligible for surgical exploration: 1) ≥50% reduction in pretreatment cancer antigen 125 (CA-125) and 2) No medical contraindications to surgery.

After surgical cytoreduction all patients will receive an additional 6 cycles of chemotherapy (cycles 4-9) regardless of disease status at the time of exploration. Chemotherapy should be re-instituted within 6 weeks of the surgical procedure. Bevacizumab will be omitted from cycle 4 of chemotherapy. Patients who do NOT undergo surgical resection should receive cycles 4-9 of therapy. In this instance bevacizumab may be included in cycle 4.

Drug: Carboplatin
Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.
Other Name: Paraplatin

Drug: Paclitaxel
Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.
Other Name: Taxol

Drug: Bevacizumab
Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.
Other Name: Avastin

Primary Outcome Measures :
  1. Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab [ Time Frame: Up to 30 days after completion of 9 cycles of treatment and/or early discontinuation (approximately up to 12 months) ]

    This is to assess the feasibility of delivering multiple cycles of the study treatment without excessive dose modification or cycle delays. The regimen would be considered unfeasible for further study if there were 5 or more of the following events within the first 15 patients, 7 or more of these events within the first 30 patients, or 8 or more of these events within the first 45 patients:

    • Delay of day 1 of therapy > 3 weeks from the expected day 1 of that cycle
    • Febrile neutropenia requiring hospitalization
    • Grade 4 thrombocytopenia
    • Grade 1-5 gastrointestinal perforation
    • Grade 3-4 hemorrhagic toxicity
    • Grade 3-4 arterial thromboembolic complications
    • Grade 4 hypertension
    • Grade 4 proteinuria
    • Fascial dehiscence

Secondary Outcome Measures :
  1. Response Rate [ Time Frame: Cycle 3, Cycle 6, Cycle 9 and 3 years post-treatment ]
    The percentage of patients whose cancer shrinks or disappears after treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

  2. Quality of Life (QOL) Score [ Time Frame: Baseline, Cycle 3, Cycle 6, Cycle 9 ]
    The FACT Quality of Life (QOL) Score questionnaire is designed to assess the effects of cancer and its treatment on the quality of life, by measuring aspects of an individual's sense of well-being and ability to carry out various activities. When calculating the total QOL score, the score scale of functional well-being was reversed in order to keep consistent with other three domains. The lower the total score, the better the quality of life. The five-point scale ranges from 0 (not at all) to 4 (very much). Scoring the FACT-G is performed through a simple sum of item scores. Each subscale is scored, and a total score for the FACT-G is obtained by adding each of the subscale scores. With a total possible score greater than 100, additional scoring methods have been used to simplify interpretation. Modifications of scoring include normalizing the total score on a scale of 0-100 through mathematical transformations, as well as the use of a Trial Outcome Index (TOI).

  3. Progression-free Survival (PFS) [ Time Frame: Up to 3 years ]
    The length of time during and after the treatment of cancer, that a patient lives with the disease but it does not get worse.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have Suspected Federation of Gynecology and Obstetrics (FIGO) stage III or IV disease.
  • Cytologic or histologic diagnosis of a carcinoma felt by the investigator to be compatible with epithelial cancer of the ovary, fallopian tube, or primary peritoneum
  • Patients must have a Performance Status of 0, 1 or 2.
  • Patients with prior anthracycline exposure must have a baseline multigated acquisition scan (MUGA) or echocardiogram prior to study entry.
  • Patients must have adequate:

    • Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1500/υl, equivalent to Common Toxicity Criteria for Adverse Events v3.0 (CTCAE) Grade 1. This ANC cannot have been induced or supported by granulocyte colony stimulating factors.
    • Platelets greater than or equal to 100,000/υl (CTCAE Grade 0-1).
    • Hematocrit > 21%.
    • Renal function: Creatinine < 1.5 x institutional upper limit of normal (ULN), CTCAE Grade 1.
    • Hepatic function: Bilirubin less than or equal to 1.5 x ULN (CTCAE Grade 1). AST, ALT, and alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE Grade 1). Aspartate transaminase (AST) and alanine transaminase (ALT)
    • Neurologic function: Neuropathy (sensory and motor) less than or equal to CTCAE Grade 1.
    • Coagulation function: Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) - PT such that international normalized ratio (INR) is ≤ 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolism) and a PTT < 1.2 times the upper limit of normal.
  • Patients must have measurable disease. Patients may or may not have cancer-related symptoms.
  • Baseline CA-125 must be ≥ 70 units/mL.
  • Patients must have met all pre-entry requirements.
  • An approved informed consent and authorization permitting release of personal health information must be signed by the patient or guardian.
  • Eligible patients should be deemed as likely to be medically fit to undergo surgical cytoreduction after 3 cycles of neoadjuvant chemotherapy by a surgical gynecologic oncologist.
  • Patients may receive estrogen +/- progestin replacement.

Exclusion Criteria:

  • Patients should NOT have undergone any prior cancer directed surgery (exploration, debulking, etc), with the exception of a minor procedure such as biopsy or cytology specimen.
  • Patients who have received prior chemotherapy, immunotherapy, radiotherapy, hormonal therapy or biologic therapy for their ovarian or primary peritoneal cancer are not eligible.
  • Patients with borderline ovarian tumors, recurrent epithelial ovarian or primary peritoneal cancer or non-epithelial ovarian cancer are not eligible.
  • Patients with a CA125:CEA ratio <25. Carcinoembryonic Antigen (CEA)
  • Patients with other cancers (other than non-melanoma skin cancer) within the last five years.
  • Patients with acute hepatitis or end stage liver disease.
  • Patients with serious non-healing wound, ulcer or bone fracture. This includes history of abdominal fistula or intra-abdominal abscess within 6 months. Patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations.
  • History of prior gastrointestinal perforation.
  • Patients with evidence of abdominal free air not explained by paracentesis.
  • Patients with signs or symptoms of gastrointestinal obstruction including those receiving total parenteral nutrition (TPN), intravenous hydration or tube feeds.
  • Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels by imaging, regardless of whether any chance of requiring vascular reconstruction.
  • Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study. Patients with treated brain metastases can enter the study. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating physician. Patients with central nervous system (CNS) metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded.
  • Patients with clinically significant cardiovascular disease. This includes:

    • Uncontrolled hypertension, defined as systolic > 140 mm Hg or diastolic > 90 mm Hg.
    • Myocardial infarction or unstable angina within 6 months of day 1 prior to registration.
    • New York Heart Association (NYHA) Grade II or greater congestive heart failure.
    • Serious cardiac arrhythmia requiring medication. This does not include atrial fibrillation.
    • CTCAE Grade 3 or greater peripheral vascular disease.
    • History of CVA within six months.
  • Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies including hypersensitivity to any component of bevacizumab
  • Patients with clinically significant proteinuria. Urine protein should be screened by urine protein-creatinine ratio (UPCR). The UPCR has been found to correlate directly with the amount of protein excreted in a 24 hour urine collection. Specifically, a UPCR of 1.0 is equivalent to 1.0 grams of protein in a 24 hour urine collection. Obtain at least 4 ml of a random urine sample in a sterile container (does not have to be a 24 hour urine). Send sample to lab with request for urine protein and creatinine levels (separate requests). The lab will measure protein concentration (mg/dL) and creatinine concentration (mg/dL). The UPCR is derived as follows: protein concentration (mg/dL)/creatinine (mg/dL). Patients must have a UPCR < 1.0 to allow participation in the study.
  • Patients with hypertensive crises or hypertensive encephalopathy
  • History of hemoptysis (≥ ½ teaspoon of bright red blood per episode) within 1 month prior to day 1.
  • Patients with or with anticipation of a non-study related invasive procedure defined as followed:

    • Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab.
    • Major non-study related surgical procedure anticipated during the course of the study.
    • Core biopsy within 7 days prior to first date of bevacizumab.
  • Patients with a Performance Status of Grade 3 or 4 are not eligible.
  • Patients who are pregnant or nursing. Subjects of child-bearing age have to use effective means of contraception.
  • Patients under the age of 18.
  • Patients who have received prior therapy with any anti-VEGF drug, including bevacizumab. Vascular endothelial growth factor (VEGF)
  • Patients with human immunodeficiency virus (HIV).
  • Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study. The investigator should consult the Study Chair.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01146795

Layout table for location information
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Jason D. Wright
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Jason D Wright, MD Columbia University
Layout table for additonal information
Responsible Party: Jason D. Wright, Sol Goldman Associate Professor of Gynecology Oncology (in Obstetrics and Gynecology), Columbia University Identifier: NCT01146795    
Other Study ID Numbers: AAAD8429
First Posted: June 22, 2010    Key Record Dates
Results First Posted: February 9, 2021
Last Update Posted: February 9, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Fallopian Tube Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs